Evidence map›Paper›PMID 23963136›Full record

ArticleCritical care medicine2013

P2X7 receptor antagonism inhibits p38 mitogen-activated protein kinase activation and ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats.

Sheng Chen, Qingyi Ma, Paul R Krafft, Yujie Chen, Jiping Tang, Jianmin Zhang, John H Zhang

Abstract read
In one paragraph

Article in Critical care medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Electroacupuncture regulates the P2XPurinergic signalling · 2025
    Article
  3. The Regulatory Mechanisms of Treponema pallidum Enolase on Macrophages: From Enzymatic Activity to Signal Transduction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. P2XFrontiers in cellular neuroscience · 2021
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sheng Chen1Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 2Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA.
Qingyi Ma
Paul R Krafft
Yujie Chen
Jiping Tang
Jianmin Zhang
John H Zhang
Loma Linda University · USSecond Affiliated Hospital of Zhejiang University · CN

Funding

Neurovascular Protection for Subarachnoid HemorrhageR01NS053407 · NINDS · LOMA LINDA UNIVERSITY · PI ZHANG, JOHN H · 2006 to 2010
$1.8M
Neurovascular Protection for Early Brain Injury after SAHR01NS081740 · NINDS · LOMA LINDA UNIVERSITY · PI ZHANG, JOHN H · 2013 to 2017
$1.6M
NINDS NIH HHS R01 NS053407NINDS NIH HHS R01 NS081740
6 · The paper itself

Abstract

objectivesBrilliant blue G, a selective P2X7 receptor antagonist, exhibits neuroprotective properties. This study examined whether brilliant blue G treatment ameliorates early brain injury after experimental subarachnoid hemorrhage, specifically via inhibiting p38 mitogen-activated protein kinase-related proapoptotic pathways.

designControlled in vivo laboratory study.

settingAnimal research laboratory. SUBJECTS: One hundred fifty-four adult male Sprague-Dawley rats weighing 280-320 g.

interventionsSubarachnoid hemorrhage was induced in rats by endovascular perforation. Experiment 1 implemented sham-operated rats (sham) and subarachnoid hemorrhage animals, which received vehicle (subarachnoid hemorrhage + vehicle), brilliant blue G (subarachnoid hemorrhage + brilliant blue G), or brilliant blue G plus 2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-triphosphate (BzATP) (subarachnoid hemorrhage + brilliant blue G + BzATP). The animals were intraperitoneally treated with brilliant blue G (30 mg/kg) at 30 minutes after subarachnoid hemorrhage. BzATP (50 μg/rat), a P2X7 receptor agonist, was intracerebroventricularly administered. Experiment 2 implemented sham-operated rats (sham) and subarachnoid hemorrhage animals, which received vehicle (subarachnoid hemorrhage + vehicle), scramble small interfering RNA (subarachnoid hemorrhage + scramble small interfering RNA), or P2X7 receptor small interfering RNA (subarachnoid hemorrhage + P2X7 receptor small interfering RNA). Subarachnoid hemorrhage grading, neurobehavioral score, and brain edema were evaluated at 24 and 72 hours after surgery. The expression of phosphorylated p38 mitogen-activated protein kinase, phosphorylated extracellular signal-regulated kinases, phosphorylated c-Jun N-terminal kinases, P2X7 receptor, Bcl-2, and cleaved caspase-3 in the left cerebral hemisphere were determined by Western blot. Neuronal apoptosis was examined by double immunofluorescence staining using P2X7 receptor, terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling, and neuronal nuclei. MEASUREMENTS AND MAIN

resultsBrilliant blue G significantly improved neurobehavioral function and ameliorated brain water content at 24 and 72 hours after subarachnoid hemorrhage. BzATP reversed these treatment effects. Brilliant blue G attenuated neuronal apoptosis in the subcortex, which was associated with decreased expression of phosphorylated p38 mitogen-activated protein kinase and cleaved caspase-3 and an increased expression of Bcl-2 in the left cerebral hemisphere. The beneficial effects of P2X7 receptor small interfering RNA were also mediated by a p38 mitogen-activated protein kinase pathway.

conclusionsInhibition of P2X7 receptor by brilliant blue G or P2X7 receptor small interfering RNA can prevent early brain injury via p38 mitogen-activated protein kinase after subarachnoid hemorrhage.

Indexed as

Adenosine TriphosphateAnimalsApoptosisCaspase 3Enzyme ActivationExtracellular Signal-Regulated MAP KinasesJNK Mitogen-Activated Protein KinasesMaleNeuronsp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-bcl-2Purinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsRatsRats, Sprague-DawleyReceptors, Purinergic P2X73'-O-(4-benzoyl)benzoyladenosine 5'-triphosphateAdenosine TriphosphateCaspase 3coomassie Brilliant BlueExtracellular Signal-Regulated MAP KinasesJNK Mitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-bcl-2Purinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7RNA, Small InterferingRosaniline Dyes

Identifiers

PMID23963136
PMCPMC3841260
OpenAlexW2066349132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.